Zivo Bioscience- Warrants (29/04/2026) EBIT

The latest EBIT for ZIVOW is $-5.5M as of June 2026. That compares with $-9.7M in the prior-year period — up 43.4% year over year. That is below the Consumer Discretionary sector average of $150B. Investors often review this figure alongside Zivo Bioscience- Warrants (29/04/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ZIVOW's EBIT moved from $-9.7M to $-5.5M — a 43.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zivo Bioscience- Warrants (29/04/2026)'s operating scale or balance-sheet position.

Against Consumer Discretionary companies, ZIVOW currently prints $-5.5M for EBIT, while the sector average sits near $150B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Zivo Bioscience- Warrants (29/04/2026)'s growth, margins, and balance sheet.

A EBIT figure of $-5.5M for ZIVOW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Consumer Discretionary average is about $150B. Explore the charts below for those layers of context.

After noting ZIVOW's EBIT ($-5.5M), review year-over-year change from $-9.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.